CN114796481A - 治疗阿尔茨海默病的方法 - Google Patents

治疗阿尔茨海默病的方法 Download PDF

Info

Publication number
CN114796481A
CN114796481A CN202210397569.0A CN202210397569A CN114796481A CN 114796481 A CN114796481 A CN 114796481A CN 202210397569 A CN202210397569 A CN 202210397569A CN 114796481 A CN114796481 A CN 114796481A
Authority
CN
China
Prior art keywords
subject
aria
antibody
patient
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210397569.0A
Other languages
English (en)
Chinese (zh)
Inventor
B.P.布特
J.J.塞维尼
L.L.威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen International Neuroscience GmbH
Original Assignee
Biogen International Neuroscience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen International Neuroscience GmbH filed Critical Biogen International Neuroscience GmbH
Publication of CN114796481A publication Critical patent/CN114796481A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202210397569.0A 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法 Pending CN114796481A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US62/346,818 2016-06-07
US201662435531P 2016-12-16 2016-12-16
US62/435,531 2016-12-16
PCT/EP2017/063711 WO2017211827A1 (en) 2016-06-07 2017-06-06 Methods for treating alzheimer's disease
CN201780044190.9A CN109476730A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780044190.9A Division CN109476730A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Publications (1)

Publication Number Publication Date
CN114796481A true CN114796481A (zh) 2022-07-29

Family

ID=59067640

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210397569.0A Pending CN114796481A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法
CN201780044190.9A Pending CN109476730A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法
CN202210397435.9A Pending CN114931635A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201780044190.9A Pending CN109476730A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法
CN202210397435.9A Pending CN114931635A (zh) 2016-06-07 2017-06-06 治疗阿尔茨海默病的方法

Country Status (12)

Country Link
US (2) US20200308259A1 (https=)
EP (1) EP3464350A1 (https=)
JP (3) JP2019517540A (https=)
KR (2) KR20190021311A (https=)
CN (3) CN114796481A (https=)
AU (2) AU2017276656A1 (https=)
BR (1) BR112018075300A2 (https=)
CA (1) CA3026598A1 (https=)
IL (1) IL263433B2 (https=)
MA (1) MA45149A (https=)
MX (1) MX2018015022A (https=)
WO (1) WO2017211827A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
US20220177560A1 (en) 2019-03-26 2022-06-09 Janssen Pharmaceutica Nv Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
MX2022004678A (es) * 2019-10-22 2022-08-15 Biogen Ma Inc Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
WO2022261026A2 (en) * 2021-06-07 2022-12-15 Biogen Ma Inc. Methods for treating alzheimer's disease
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation
MX2024005999A (es) * 2021-11-19 2024-05-30 Ap Biosciences Inc Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2468770T (lt) * 2006-07-14 2018-05-25 Ac Immune S.A. Humanizuotas antikūnas prieš beta amiloidą
KR20120017469A (ko) 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
RU2689674C2 (ru) * 2012-10-15 2019-05-28 Медиммьюн Лимитед Антитела к бета-амилоиду
CN105979962A (zh) * 2012-12-07 2016-09-28 比奥根国际神经科学公司 使用抗Aβ抗体减少脑淀粉样蛋白斑块的方法
PT2935326T (pt) 2012-12-21 2020-09-14 Biogen Ma Inc Anticorpos anti-tau humanos
RU2724190C2 (ru) * 2014-02-08 2020-06-23 Дженентек, Инк. Способы лечения болезни альцгеймера
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
JP2019517540A (ja) 2019-06-24
IL263433B2 (en) 2024-03-01
US20200308259A1 (en) 2020-10-01
AU2017276656A1 (en) 2018-12-13
AU2024216442A1 (en) 2024-10-17
JP2022145965A (ja) 2022-10-04
CN114931635A (zh) 2022-08-23
WO2017211827A1 (en) 2017-12-14
CA3026598A1 (en) 2017-12-14
JP2025160337A (ja) 2025-10-22
KR20190021311A (ko) 2019-03-05
CN109476730A (zh) 2019-03-15
KR20230165883A (ko) 2023-12-05
MA45149A (fr) 2019-04-10
EP3464350A1 (en) 2019-04-10
IL263433A (en) 2019-01-31
MX2018015022A (es) 2019-08-14
US20220281963A1 (en) 2022-09-08
IL263433B1 (en) 2023-11-01
BR112018075300A2 (pt) 2019-04-30

Similar Documents

Publication Publication Date Title
US20260091109A1 (en) Method for Treating Alzheimer's Disease
US20220281963A1 (en) Methods for treating alzheimer's disease
CN114599393A (zh) 治疗阿尔茨海默病的抗β-淀粉样蛋白抗体
JP2025506389A (ja) ｐ－タウ１８１レベルを使用した治療方法
JP2024540294A (ja) アルツハイマー病を治療するための方法
TW202313111A (zh) 治療阿茲海默症之方法
NZ788486A (en) Methods for treating Alzheimer's disease
CN118829445A (zh) 用于治疗阿尔茨海默病的方法
EA051351B1 (ru) Способ лечения болезни альцгеймера

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination